Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study (Q39355934)

11 September 2017

Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study (English)

1 reference

extensively drug-resistant tuberculosis

11 September 2017

0 references

0 references

1 reference

Maia Lesosky

8

0 references

Elizabeth Streicher

Elizabeth M Streicher

3

0 references

Robin M. Warren

Robin Warren

11

0 references

Keertan Dheda

12

Keertan Dheda

1 reference

11 September 2017

Motasim Badri

7

1 reference

ORCID Public Data File 2021

Paul van Helden

9

Paul van Helden

1 reference

11 September 2017

Elize Pietersen

1

1 reference

11 September 2017

Elisa Ignatius

2

1 reference

11 September 2017

Barbara Mastrapa

4

1 reference

11 September 2017

Xavier Padanilam

5

1 reference

11 September 2017

Anil Pooran

6

1 reference

11 September 2017

Frederick A Sirgel

10

1 reference

11 September 2017

language of work or name

English

0 references

publication date

17 January 2014

1 reference

11 September 2017

1 reference

11 September 2017

383

1 reference

11 September 2017

9924

1 reference

11 September 2017

1230-1239

1 reference

Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa

11 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Safe Mycobacterium tuberculosis DNA extraction method that does not compromise integrity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Canadian multicenter laboratory study for standardized second-line antimicrobial susceptibility testing of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Totally drug-resistant tuberculosis in India.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Mutations in the rrs A1401G Gene and Phenotypic Resistance to Amikacin and Capreomycin in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Comprehensive treatment of extensively drug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Linezolid for treatment of chronic extensively drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

The re-emergence of tuberculosis: what have we learnt from molecular epidemiology?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962675-6

7 January 2021

10.1016/S0140-6736(13)62675-6

Identifiers

DOI

1 reference

11 September 2017

1 reference